These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37041352)

  • 21. Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials.
    Garmendia CA; Nassar Gorra L; Rodriguez AL; Trepka MJ; Veledar E; Madhivanan P
    JAMA Intern Med; 2019 Apr; 179(4):582-584. PubMed ID: 30830216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA standards--good enough for government work?
    Avorn J
    N Engl J Med; 2005 Sep; 353(10):969-72. PubMed ID: 16148281
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA ruling dealing with the food labeling of fats and oils.
    Robertson CJ
    Prev Med; 1972 Mar; 1(1):244-7. PubMed ID: 5069009
    [No Abstract]   [Full Text] [Related]  

  • 24. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA states policy on pharmacy compounding. Agency follows up on supreme court ruling.
    Young D
    Am J Health Syst Pharm; 2002 Jul; 59(13):1222, 1224. PubMed ID: 12116887
    [No Abstract]   [Full Text] [Related]  

  • 26. Concern over Prozac-induced tumor growth may dwindle following FDA study.
    Mathews J
    J Natl Cancer Inst; 1995 Sep; 87(17):1285-7. PubMed ID: 7658480
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA grants accelerated approval for ibrutinib for CLL.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
    [No Abstract]   [Full Text] [Related]  

  • 28. Supreme court ruling on FDA oversight of tobacco.
    Meier E
    Pediatr Nurs; 2000; 26(4):414. PubMed ID: 12026480
    [No Abstract]   [Full Text] [Related]  

  • 29. Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System.
    Cheng C; Woronow D; Nayernama A; Wroblewski T; Jones SC
    Leuk Lymphoma; 2018 Dec; 59(12):3016-3017. PubMed ID: 29792382
    [No Abstract]   [Full Text] [Related]  

  • 30. Esketamine for treatment resistant depression.
    Jauhar S; Morrison P
    BMJ; 2019 Sep; 366():l5572. PubMed ID: 31548292
    [No Abstract]   [Full Text] [Related]  

  • 31. Ruling gives FDA discretion in drug withdrawals.
    Cima G
    J Am Vet Med Assoc; 2014 Sep; 245(6):623. PubMed ID: 25322490
    [No Abstract]   [Full Text] [Related]  

  • 32. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 33. An ingredient under fire. Drugmakers are jittery after an FDA panel ruling.
    Noonan D
    Newsweek; 2000 Oct; 136(18):59. PubMed ID: 11185358
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA approves first celecoxib generics.
    Kuehn BM
    JAMA; 2014 Jun; 311(24):2470. PubMed ID: 25058066
    [No Abstract]   [Full Text] [Related]  

  • 35. US drug industry and FDA prepare for closer ties.
    Ashraf H
    Lancet; 2002 Jun; 359(9321):1923. PubMed ID: 12057560
    [No Abstract]   [Full Text] [Related]  

  • 36. Coming closer to FDA reform.
    Cimmons M
    Nat Med; 1997 Sep; 3(9):940. PubMed ID: 9288707
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of Flibanserin: Science and Advocacy at the FDA.
    Gellad WF; Flynn KE; Alexander GC
    JAMA; 2015 Sep; 314(9):869-70. PubMed ID: 26148201
    [No Abstract]   [Full Text] [Related]  

  • 38. A Divisive Ruling on Devices -
    Zettler PJ; Adashi EY; Cohen IG
    N Engl J Med; 2021 Dec; 385(26):2409-2411. PubMed ID: 34818475
    [No Abstract]   [Full Text] [Related]  

  • 39. Antidepressants and the placebo response.
    Kirsch I
    Epidemiol Psichiatr Soc; 2009; 18(4):318-22. PubMed ID: 20170046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA advisers endorse Celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns.
    Young D
    Am J Health Syst Pharm; 2007 Jan; 64(1):11-2. PubMed ID: 17189564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.